ZURA
Zura Bio Ltd
$3.70
+3.35%
$351.5M
No data for this timeframe.
Vol
Market Cap$351.5M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (93%)
Insider Activity1B / 0S
Insider Net $$12.5M
SEC Reports3
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. E9·CIK 0001855644·Prev Close $3.58
Recent Activity
May 7, 2026
SEC
Zura Bio reported Q1 2026 net loss of $24.2M ($0.22/share), wider than consensus estimate of -$0.17 and the year-ago los
8-K — Impact 3/10
May 7, 2026
earnings_calendar
ZURA Q1 2026 Earnings Scheduled — 2026-05-07
Apr 1, 2026
Insider
Kulkarni Sandeep Chidambar was granted 894,000 shares
Chief Executive Officer
Apr 1, 2026
Insider
Whale Gary was granted 263,000 shares
Chief Technology Officer
Apr 1, 2026
Insider
Nistala Kiran was granted 340,900 shares
See Remarks
Mar 5, 2026
SEC
Zura Bio Ltd announced that the design of its Phase 2 TibuSURE clinical trial evaluating tibulizumab (ZB-106) in systemi
8-K — Impact 4/10
Feb 26, 2026
SEC
Zura Bio Ltd (ZURA) raised approximately $134.6 million through a public offering of 18.2 million shares and pre-funded
8-K — Impact 5/10
Price Targets
$15.67
+323.4% upside
Strong Buy
Current $3.70
Low $11.00
Median $15.00
High $26.00
6 analysts
$11.00
$26.00
Analyst Ratings
6Strong Buy
7Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 23, 2026 | Chardan Capital | MAINTAIN | Buy → Buy |
| Mar 20, 2026 | Oppenheimer | MAINTAIN | Outperform → Outperform |
| Feb 9, 2026 | Wedbush | INITIATE | Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.10 | $-0.10 — $-0.10 | 1 | |
| Next Q | $-0.10 | $-0.10 — $-0.10 | 1 | |
| Current FY | $-0.44 ▲ +25.4% | $-0.44 — $-0.44 | 58% YoY | 1 |
| Next FY | $-0.10 ▲ +28.6% | $-0.10 — $-0.10 | 77% YoY | 1 |
Latest Reports
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 1, 2026 | Kulkarni Sandeep | A | $0.00 |
| Apr 1, 2026 | Whale Gary | A | $0.00 |
| Apr 1, 2026 | Nistala Kiran | A | $0.00 |
| Apr 1, 2026 | Hyllengren Eric | A | $0.00 |
| Apr 1, 2026 | Davis Kim | A | $0.00 |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
8 unique insiders with 8 transactions. Net insider value: $12.5M ($12.5M bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 1, 2026 | Kulkarni Sandeep Chidambar | Chief Executive Officer | AWARD | 894,000 | — | — |
| Apr 1, 2026 | Whale Gary | Chief Technology Officer | AWARD | 263,000 | — | — |
| Apr 1, 2026 | Nistala Kiran | See Remarks | AWARD | 340,900 | — | — |
| Apr 1, 2026 | Hyllengren Eric J | Chief Financial Officer | AWARD | 340,900 | — | — |
| Apr 1, 2026 | Davis Kim | Chief Legal Officer | AWARD | 425,700 | — | — |
| Feb 26, 2026 | AI Biotechnology LLC | 10%+ Owner | BUY | 2,000,000 | $6.25 | $12.5M |
| Feb 21, 2026 | Nirula Ajay | Director | AWARD | 37,812 | — | — |
| Feb 21, 2026 | Eisner Mark | Director | AWARD | 37,812 | — | — |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 4.0/10.
NEUTRAL
8-K
3/10
Zura Bio reported Q1 2026 net loss of $24.2M ($0.22/share), wider than consensus estimate of -$0.17
May 7, 2026
NEUTRAL
8-K
4/10
Zura Bio Ltd announced that the design of its Phase 2 TibuSURE clinical trial evaluating tibulizumab
Mar 5, 2026
NEUTRAL
8-K
5/10
Zura Bio Ltd (ZURA) raised approximately $134.6 million through a public offering of 18.2 million sh
Feb 26, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (93% buy). Based on 14 analysts: 6 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$15.67 mean target
+323.4% upside
Strong Buy (1.14)
$11.00 Low
$26.00 High
| Metric | Value |
|---|---|
| Current Price | $3.70 |
| Target Low | $11.00 |
| Target Mean | $15.67 |
| Target Median | $15.00 |
| Target High | $26.00 |
| # Analysts | 6 |
| Recommendation | Strong Buy (1.14) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.10 | $-0.10 | $-0.10 | — | — | — | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-0.10 | $-0.10 | $-0.10 | — | — | — | $0.0B | 0.0% | 1 |
| Current FY 2026-12-31 |
$-0.44 | $-0.44 | $-0.44 | 58.5% | +25.4% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Next FY 2027-12-31 |
$-0.10 | $-0.10 | $-0.10 | 77.3% | +28.6% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.100 | |
| 7d ago | $0.000 | -0.100 |
| 30d ago | $0.000 | -0.100 |
| 60d ago | $0.000 | -0.100 |
| 90d ago | $0.000 | -0.100 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 23, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Mar 20, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Feb 9, 2026 | Wedbush | INITIATE | — | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 7 | 1 | 0 | 0 | 93% | |
| May 1, 2026 | 6 | 7 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 6 | 7 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 6 | 7 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 5 | 7 | 1 | 0 | 0 | 92% | |
| Jan 1, 2026 | 5 | 7 | 1 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 7, 2026
earnings_calendar
ZURA Q1 2026 Earnings Scheduled — 2026-05-07
May 6, 2026
earnings_calendar
ZURA Q1 2026 Earnings Scheduled — 2026-05-06